Clinical trial
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients…
NCT00063609 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00063609 |
|---|---|
| Title | The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy |
| Official title | The Effect of Zoledronic Acid Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | zoledronic acid |
| Enrollment | 200 |
| Start date | Apr 1, 2003 |
| Completion | Apr 1, 2005 |
| First posted | Jul 3, 2003 |
| Last update posted | Sep 13, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: